MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. PharmaLogic Ltd. 2. 1191 S. Brownell Road, Suite 40 Williston, VT 05495				In accorda June 14, 20	nce with letter dated 018.	4. Expiration Date: November 30, 2024 5. Docket No.: 030-33449 Reference No.:		
					number: 44-30124-01MD ded in its entirety to read vs:			
6.	Byproduct, source, and/or special nuclear material	7.	Chemical and/or physical t	orm	Maximum amount that license may possess at any one time under this license	e ·	Authorized use	
Α.	Any byproduct material between Atomic Numbers 3 and 83 with Exceptions	A.	Any Except Sealed Sou		A. 200 millicuries per source and 2 curies total		For preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.	
B.	Fluorine-18	B.	Any		B. 1 curie total	B.	For preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.	
C.	Gallium-67	C.	Any		C. 500 millicuries total	C.	For preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.	

NRC	FORM 374A			U.S. NUCLEA	REGU	LATORY COMMI	SSION		PAGE 5 OF 9 PAGES
	MATERIALS LICENSE SUPPLEMENTARY SHEET			License Number 44-30124-01MD Amendment No. 35		Docket or Reference Number 030-33449			
6. P.	Byproduct, source, and/or special nuclear material Any byproduct material	7. P.		/or physical form	8.				Authorized use For redistribution of sealed sources
	permitted in 10 CFR 35.400		Brachytheran 1251; IsoAid IAI-125A; No Scientific, Ind	oy, Model STM , LLC, Model orth American c., Model MED 3631 CTheragenics, seed 200)					initially distributed by a manufacturer licensed in accordance to 10 CFR 32.74 to authorized recipients for medical use. For redistribution of sealed sources that have been registered either with NRC under 10 CFR 32.210 or with an Agreement State and have been distributed in accordance with an NRC or Agreement State specific license authorizing distribution to persons specifically authorized by an NRC or Agreement State license to receive, possess and use the authorized device.
Q.	Any byproduct material between atomic numbers 2 & 83 with exceptions	Q.	Analytical Sa	imples	Q.	50 millicuries	total	Q.	For possession incident to the performance of tests for leakage on customers sealed sources.
R.	Uranium- depleted in Uranium-235	R.	Metal		R . ≧ ₹	400 kilogram	s total	R.	For shielding of molybdenum-99/technetium-99m generators .
S.	Germanium-68	S.	Any		S.	100 millicurie	es total	S.	For use of the Eckert and Ziegler GalliaPharm™ generator to prepare Ga-68 radiopharmaceuticals for imaging and localization studies.
Т.	Gallium-68	Т.	Any		T.	100 millicurie	es total	T.	For preparation and distribution of radioactive drugs in accordance with 10 CFR 32.72 and radiochemicals for non-medical use to authorized recipients.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COM	IMISSION	PAGE 6 OF 9 PAGES						
MATERIALS LICENSE	License Number 44-30124-01MD	Docket or Reference Number 030-33449							
SUPPLEMENTARY SHEET	Amendment No. 35								
	CONDITIONS								
10. Licensed material may be used or sto	ored at the licensee's facilities located at 1	191 S. Brownell Road, Suite 40	Williston Vermont						
		A A	,						
11. Licensed material shall only be used	ensed material shall only be used by, or under the supervision of:								
The Electrical Material Shall only be used	by, or unique the supervision or.								
A Δ pharmacist working or designate	A. A pharmacist working or designated as an authorized nuclear pharmacist in accordance with 10 CFR 32.72(b)(2)(i) or (4).								
7. A pharmacist working or designate		Passonance with 10 Of 10 02:12	(5)(2)(1) 61 (+).						
B. Authorized Nuclear Pharmacists:		A Committee of the Comm							
Steven C. Green, R.Ph.	Robert S. Hickman, Pharm.D.	Bynum L. Kim	mons, R.Ph.						
Joseph Olinzock, Pharm.D.	Glen Palmer (P.Dh.	Ruth Mary We							
Zonker White, R.Ph.	Cienti annet, warne	and the second of the second o	·						
	and the second s	The same of the sa							
C. Authorized Users working under t	C. Authorized Users working under the supervision of an authorized nuclear pharmacist								
James Cordonier, II, R.Ph.	David Ellis, R.Ph.	Kevin Hart, R.	Ph.						
Garth Kistner, R.Ph.	Peteris Kruze, R.Ph.	Laurie Stalling	gs, R.Ph., BCNP						
Timothy Summers, R.Ph.	Dana Suttle, R.Ph.	Tamiko Ushio	, R.Ph.						

- 12. The Radiation Safety Officer (RSO) for this license is Robert S. Hickman, Pharm.D.
- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 14. This license does not authorize distribution to persons exempt from licensing.

- 15. A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State. In the absence of a registration certificate, sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months, or at such other intervals as specified.
 - B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
 - C. Sealed sources need not be tested if they contain only hydrogen 3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
 - D. Sealed sources need not be tested if they are in storage and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
 - E. The leak test shall be capable of detecting the presence of 185 becquerels (0.005 microcuries) of radioactive material on the test sample. If the test reveals the presence of 185 becquerels (0.005 microcuries) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
 - F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
 - G. Records of leak test results shall be kept in units of becquerels (microcuries) and shall be maintained for 3 years.

- 16. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.
- 17. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sealed sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
- 18. The licensee is authorized to hold radioactive material with a physical half-life of less than or equal to 120 days for decay-in-storage before disposal in ordinary trash provided:
 - A. Before disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated, except for radiation labels on materials that are within containers and that will be managed as biomedical waste after they have been released from the licensee.
 - B. A record of each such disposal permitted under this license condition shall be retained for 3 years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.
- 19. The licensee is authorized to retrieve, receive and dispose of radioactive waste from its customers, limited to radiopharmacy-supplied syringes and vials and their contents.
- 20. Notwithstanding the requirements of 10 CFR 30.35(a)(1), the licensee is exempt from the requirement to have a decommissioning funding plan needed for the possession and use of Ge-68/Ga-68 medical use generators (Eckert and Ziegler GalliaPharm™ generators), based on the commitments between the licensee and manufacturer (Eckert and Ziegler). The licensee shall return the generators to the manufacturer/distributor in accordance with the generator return agreement described in the letter dated July 10, 2018.

- 21. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application dated November 16, 2012 ML12342A318]
 - B. Letter dated January 18, 2013 [ML13024A274]
 - C. Letter dated October 30, 2014 [ML14321A541]
 - D. Letter dated November 7, 2014 [ML14323A351]
 - E. Letter dated January 20, 2015 [ML15048A172]
 - F. Letter received March 20, 2015 [ML 15090A727]
 - G. Letter dated June 14, 2018 [ML18180A337]
 - H. Letter dated July 10, 2018 [ML18207A701]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Region 1

Date: August 7, 2018